Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase )
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von María Teresa Yuste und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Murcia, Murcia, Spain. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Alzheimer Disease, Dementia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
Aromatase inhibitors are used for patients with hormone‐receptor positive breast cancer. Alzheimer's disease is the most prevalent cause of dementia. Several studies have suggested an association between the use of aromatase inhibitors and the development of Alzheimer's disease. The objective of this study was to identify potential pharmacovigilance signals associated with dementia and Alzheimer's disease and third‐generation aromatase inhibitors in menopausal and postmenopausal women. VigiBase, the global database of individual case safety reports of the World Health Organization, was used to investigate this possible association. A disproportionality analysis was performed for women aged 45 years and older. The reporting odds ratio (ROR) and its 95% CI for reporting dementia are exemestane, 2.08 (1.35–3.19); anastrozole, 1.59 (1.09–2.32); and letrozole, 1.43 (1.05–1.95) and for Alzheimer's disease are exemestane, 0.94 (0.30–2.92); anastrozole: 2.63 (1.55–4.45); and letrozole, 1.33 (0.76–2.35). For senile dementia, only letrozole has cases, with an ROR of 6.77 (2.51–18.31). Signals of disproportionate reporting have been observed between the occurrence of dementia, dementia Alzheimer's type, and senile dementia with aromatase inhibitors, which is in line with estrogen functions and aromatase activity, as well as the findings from preclinical studies. Additional research is required to elucidate this intricate matter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Murcia, Murcia, Spain.
- Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, Centre for Research on Drug Safety…
ORCID-Profile: María Teresa Yuste, María Sainz-Gil, Elisa Escudero, Pedro Marín
Zitieren
APA
Yuste, M. T., Sainz-Gil, M., Escudero, E., & Marín, P. (2025). Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase ). Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70075
Vancouver
Yuste MT, Sainz-Gil M, Escudero E, Marín P. Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase ). Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70075
BibTeX
@article{Yuste2025,
author = {Yuste, María Teresa and Sainz-Gil, María and Escudero, Elisa and Marín, Pedro},
title = {Dementia and Alzheimer's Disease Associated With Aromatase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database ( VigiBase )},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70075}
}
EUVIMED